Market capitalization | $82.80m |
Enterprise Value | $-87.59m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.84 |
P/B ratio (TTM) P/B ratio | 0.42 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-79.18m |
Free Cash Flow (TTM) Free Cash Flow | $-47.50m |
Cash position | $183.66m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
7 Analysts have issued a PMV Pharmaceuticals Inc forecast:
7 Analysts have issued a PMV Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.46 -1.46 |
51%
51%
|
|
EBITDA | -78 -78 |
5%
5%
|
EBIT (Operating Income) EBIT | -79 -79 |
4%
4%
|
Net Profit | -51 -51 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. It combines unique biological understanding with pharmaceutical development focus. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in 2013 and is headquartered in New Jersey, NY.
Head office | United States |
CEO | David Mack |
Employees | 63 |
Founded | 2013 |
Website | www.pmvpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.